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Abstract
Oxidative stress is a common denominator in the pathology of neurodegenerative disorders such as Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and multiple sclerosis, as well as in
ischemic and traumatic brain injury. The brain is highly vulnerable to oxidative damage due to its high metabolic
demand. However, therapies attempting to scavenge free radicals have shown little success. By shifting the focus to
inhibit the generation of damaging free radicals, recent studies have identified NADPH oxidase as a major contributor
to disease pathology. NADPH oxidase has the primary function to generate free radicals. In particular, there is growing
evidence that the isoforms NOX1, NOX2, and NOX4 can be upregulated by a variety of neurodegenerative factors. The
majority of recent studies have shown that genetic and pharmacological inhibition of NADPH oxidase enzymes
are neuroprotective and able to reduce detrimental aspects of pathology following ischemic and traumatic brain
injury, as well as in chronic neurodegenerative disorders. This review aims to summarize evidence supporting the
role of NADPH oxidase in the pathology of these neurological disorders, explores pharmacological strategies of
targeting this major oxidative stress pathway, and outlines obstacles that need to be overcome for successful
translation of these therapies to the clinic.
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Background
Neurodegenerative disorders such as stroke, traumatic
brain injury (TBI), Alzheimer’s disease (AD), Parkinson’s
disease (PD), Huntington’s disease (HD), amyotrophic
lateral sclerosis (ALS), and multiple sclerosis (MS) carry
substantial disease burden, not only in terms of health
suffering but also in economic costs [1–6]. Although the
clinical manifestations differ for these disorders, a com-
mon denominator in their pathology is the induction of
oxidative stress [7, 8]. For the past several decades, evi-
dence has accumulated supporting oxidative stress as an
underlying common denominator of brain injury and
neurodegenerative disorders. For instance, a keyword
search on PubMed using the terms “oxidative stress and
neurodegeneration” or “oxidative stress and brain injury”
yielded over 8,400 citations, with approximately half of
these occurring in the last five years. From this body of
research, it has become clear that pathological condi-
tions such as ischemia, trauma, and neurodegenerative
processes, markedly enhances generation of ROS in the
brain [9, 10]. Therapies attempting to target oxidative
stress have typically focused on compounds that scav-
enge the free radicals to eliminate them from the sys-
tem. Unfortunately, these therapies have generally
been unsuccessful in clinical trials despite promise in
animal models.
The lack of success to date of clinical trials using
ROS scavenging drugs has led to the hypothesis that
inhibition of the generation, rather than the scavenging,
of ROS may be a more successful avenue of therapy.
Correlative to this hypothesis, many laboratories have
focused on enhancing our understanding of the role of
ROS-generating pathways in various pathological situa-
tions. These studies have led to the identification of the
enzyme, nicotinamide adenine dinucleotide phosphate
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(NADPH) oxidase as a major generator of ROS that
contributes to the pathology of both acute brain injury
and chronic neurodegenerative disorders [11, 12].
While NADPH oxidase undoubtedly contributes to
physiological processes in the brain [13, 14], the pri-
mary goal of the current review is to summarize the
evidence supporting a role of NADPH oxidase following
acute ischemic and traumatic brain injury, as well as in
chronic neurodegenerative disorders, and explore the
potential efficacy and strategies for therapeutic targeting
of this major ROS-generating pathway.
Origin and cellular consequence of oxidative stress in
brain injury and neurodegenerative disorders
ROS are generated endogenously from molecular oxygen
by cellular oxidases, mono- and di-oxygenases of the
mitochondrial electron chain transport system, or peroxi-
dases. The major ROS involved in oxidative stress include
superoxide anion, hydrogen peroxide, and hydroxyl radi-
cals [15]. There are also reactive nitrogen species (RNS)
such as nitric oxide and peroxynitrite that participate in
oxidative stress in the CNS and throughout the body
[10, 16]. As shown in Fig. 1a, there are multiple sources
a
b
Fig. 1 a Cellular Sources of ROS. ROS can be generated intracellularly via the action of various organelles, enzymes, and processes. b Conversion
of Superoxide to Secondary ROS. Once produced, superoxide can interact with various molecules to generate secondary radicals. Superoxide can
react with nitric oxide to produce peroxynitrite. Superoxide dismutase can also convert superoxide into hydrogen peroxide, which can then undergo
a Fenton reaction to produce hydroxyl radicals and ions. Interaction of superoxide with protons can produce hydroperoxyl radicals. These secondary
radicals are highly reactive and can be neurotoxic via alterations of macromolecules and amplification of oxidative stress
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and processes that lead to generation of superoxide and
ROS in cells. Superoxide, once produced, can cause
oxidative damage directly, or it can interact with other
molecules to generate “secondary” radicals via enzymatic
or metal-catalyzed reactions. Along these lines, as shown
in Fig. 1b, superoxide can react with nitric oxide to
generate the RNS peroxynitrite, which is highly reactive,
and when over-produced can deleteriously nitrate most
biological molecules in all parts of the body, including the
brain [16, 17]. Superoxide can also undergo dismutation
via superoxide dismutase to form oxygen and hydrogen
peroxide [18]. Hydrogen peroxide is highly permeable
through cell membranes and can directly damage cells
through oxidation of deoxyribonucleic acid (DNA), pro-
teins, and lipids. In the presence of transition metals,
hydrogen peroxide can generate highly reactive hydroxyl
radicals, which can damage DNA and other molecules in
the cell [19, 20]. In addition to modifying and damaging
macromolecules, the unpaired electron in ROS can also
amplify oxidative damage by generating more free radi-
cals [21]. Finally, ROS-induced modifications can target
cysteine residues or oxidize thiols present in protein
components of cell signaling [22], and this alteration in
signaling can lead to a variety of downstream effects
involving gene expression and apoptosis.
The relationship between the cellular consequences
of oxidative stress and the progression of brain injury
and neurodegenerative disorders has undergone con-
tinued refinement. Extensive research has shown that
mitochondria-derived ROS are clinically relevant as an
important contributing factor for neurodegeneration in
brain injury and chronic neurodegenerative disorders.
While coverage of this topic is beyond the scope of this
review, the reader is referred to several excellent reviews
written previously on this subject [23–26]. Recently, there
has been increased interest in other sources of ROS, such
as NADPH oxidase, nitric oxide synthase, cytochrome450
(cyp450), cyclooxygenase, lipooxygenase, and xanthine
oxidase [19, 27]. Of the above list, only NADPH oxidase
has as its primary function the generation of ROS, as the
others generate ROS as a byproduct [28–30]. Previous
reviews have summarized evidence of redox crosstalk
between mitochondria and NADPH oxidase that sug-
gests mitochondria may be a key player and trigger in
amplifying the burden of oxidative stress [31–33]. In
the sections below, we will focus upon evidence con-
cerning the biology, distribution and role of the various
NADPH oxidase family members in brain injury and
neurodegenerative disorders.
NADPH oxidase – an overview
The NADPH oxidase (NOX) family of enzymes are trans-
membrane carriers that transport an electron from cyto-
solic NADPH to reduce oxygen to superoxide anion [12].
To date, there are seven known members which combine
with various subunits to form active enzyme complexes -
NOX1, NOX2, NOX3, NOX4, NOX5, dual oxidase 1
(DUOX1), and DUOX2 [34–37] (Fig. 2). The NOX and
DUOX isoforms are structurally similar with each isoform
having binding sites for heme, flavin adenine dinucleotide
(FAD) and NADPH [38, 39], and 6 conserved transmem-
brane α-helices [12]. DUOX enzymes have an additional
seventh transmembrane helix and possess peroxidase
activity [12]. Once the active complex is assembled, an
electron from cytosolic NADPH is transferred to oxy-
gen on the extracellular side [12]. The distribution and
regulation of the NOX and DUOX isoforms throughout
the body and brain varies depending upon the isoform.
Table 1 summarizes the reported distribution of NOX
and DUOX isoforms throughout the body, including the
central nervous system (CNS). It also lists the major corre-
sponding regulators and products for the various isoforms.
NOX1
NOX1 generates the product superoxide, and has the
most similarity to the NOX2 and NOX3 isoforms, as evi-
denced by association with homologous regulatory sub-
units and regulation by Rac GTPase [40–42]. As shown in
Fig. 2, NOX1-3 subunits form functional dimers with
p22phox. In addition, NADPH oxidase activator 1
(NOXA1) serves as an “activator” for NOX 1 and 3 [43],
and is structurally homologous to p67 phagocytic oxidase
(p67phox), which is the activator for NOX2. NADPH
oxidase organizer 1 (NOXO1) is an “organizer” for
NOX1 and 3 [43, 44], and is structurally homologous to
p47phox and p40phox, which are organizers for NOX2.
Superoxide anion production by NOX1 has been shown
to require phosphorylation of NOXO1 by protein kinase
A (PKA) (at Ser154) or PKC (at Thr341), which then
interacts with NOXA1 to regulate NOX1 activity [45].
However, it is important to note that NOXO1 is localized
at the membrane independent of cellular activation,
which combined with its lack of auto-inhibitory func-
tion, may contribute to constitutively activated NOX1
[44]. Additional work has shown that phosphorylation
of NOXA1 on serine 282 by MAP kinases and on serine
172 by PKC down-regulates constitutive NOX1 activity
[46]. In addition, phosphorylation of NOX1 (at Thr429)
by PKC-β has been reported to be critical for NOX1
complex formation with the cytosolic regulatory units
and thus for NOX1 activation [47, 48]. Furthermore, as
shown in Fig. 2, Rac1 is also a known activator of
NOX1 [41]. Finally, a number of enzymes, cytokines,
growth factors, hormones, and cell stressors have been
implicated to also regulate NOX1 [49–60]. Functionally,
NOX1 has been implicated in pain that accompanies
inflammation, host defense via expression in microglia,
and neuronal growth [61–64]. A role for NOX1 in
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neuropathology and neurodegenerative disorders has
also been implicated and will be discussed in subse-
quent sections below.
NOX2
NOX2 (sometimes referred to by its major subunit
name - gp91phox) generates superoxide as its product
[12, 65, 66]. NOX2 is expressed in various tissues of the
body as well as several regions of the brain (see Table 1).
At the cellular level, NOX2 has been reported to be
expressed in various cell types, including neurons and
endothelial cells [67–69], and is heavily expressed in
microglia, where it is involved in immune/inflammatory
responses [70], particularly after injury [71, 72]. As shown
in Fig. 2, NOX2 has both membrane subunits (gp91phox
and p22phox) and cytosolic components (p47phox and
p67phox). During activation, a phosphorylated p47phox
interacts with p22phox, which facilitates translocation to
the membrane where p67phox can bind to p47phox to
form the active NOX2 complex [73–75]. Rac2 is coordi-
nately recruited to the membrane, where it binds directly
to p67phox and is essential for NOX2 activation [76, 77].
Binding sites for Rac2 have also been identified directly in
NOX2 [78]. NOX2 in non-phagocytic cells is structurally
similar to NOX2 of phagocytes, but its regulation may
differ. A resting endothelial cell has partially preassembled
NOX2 that generates low levels of superoxide intracellu-
larly for physiological functions rather than having func-
tional activity bound to the plasma membrane such as in
neutrophils [79]. Activation of NOX2 requires serine
phosphorylation of the p47phox subunit in models using
TNF stimulation [80, 81] and angiotensin II stimulation
[82]. Furthermore, a number of enzymes, cytokines, meta-
bolic factors, and cell stressors (hypoxia and Aβ) have
been implicated to regulate NOX2 [53, 68, 83–89]. Identi-
fied downstream targets of NOX2-derived ROS include
various kinase signaling pathways [90–95], as well as cyto-
kines and transcription factors [80, 96–99].
NOX3
In the brain, NOX3 has been reported to be expressed
in neurons in the inner ear [71], where it has been impli-
cated to play a significant role in the cochlea and vestibu-
lar system [12, 100, 101]. In support of this contention,
NOX3 knockout mice have been reported to show signs
of imbalance [102]. In addition, reduction of NOX3 has
Fig. 2 NOX isoforms and regulatory subunits. NADPH oxidases have a primary role to generate ROS. Several components and domains make up
the transmembrane active enzyme complexes of NADPH oxidase isoforms. NOX1-5 and DUOX1/DUOX2 are shown here. Upon activation, an
electron will be transferred from NADPH to O2 to form superoxide. NOX4 generated superoxide undergoes rapid conversion into hydrogen
peroxide, which mediates many of its downstream effects. NOX5 and the DUOX enzymes are sensitive to cellular Ca2+ concentrations
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been implicated to have a protective effect in cochlear
injury by reducing the amount of oxidative stress pro-
duced [103]. NOX3 generates superoxide as its product,
and the regulatory mechanism of NOX3 can involve Rac1,
NOXO1, and p67phox [40, 64, 104]. Furthermore, it has
been suggested that the p22phox subunit is critical for the
proper assembly and function of NOX3 [105, 106] (see
Fig. 2 and Table 1). Finally, NOX3 has also been reported
to be active in absence of its known regulators [104].
NOX4
NOX4 is a constitutively activated isoform [107, 108],
whose expression however is inducible. Unlike the other
NOX isoforms, the downstream effects of NOX4 are
thought to be mediated by hydrogen peroxide, due to
the rapid conversion of NOX4-generated superoxide to
hydrogen peroxide [109]. As shown in Table 1, NOX4 is
widely expressed in the body, and is expressed in various
brain regions and cells. It is reported to be a major
source of superoxide in human pericytes [110]. NOX4
requires the p22phox subunit for function [108] and has
been suggested to be inducible due to the close associ-
ation between NOX4 mRNA and ROS generation [109].
In addition, other NOX4 regulatory proteins have been
identified (Table 1), such as polymerase (DNA-directed)
delta interacting protein 2 (Poldip2) [111], protein
Table 1 Tissue and cellular distribution of NOX isoforms








Superoxide Colon [35, 39, 42]
















Superoxide Vasculature [365, 366]
Phagocytes [319, 367]






Cerebral cortex [71, 374, 375]
Hippocampus [132, 374, 376]
Cerebellum [363]
Striatum [377, 378]





















Hydrogen peroxide Ubiquitous, including:
Kidney [35, 39, 388]
Vessels [389, 390]
Lung [391–394]
Bone [39, 362, 395]
Placenta [35, 39, 396]
Cochlea [103]
Cerebral cortex [71, 377, 397]
Hippocampus [376]
Cerebellum [363]

















Hydrogen peroxide Thyroid [34, 37]
Lung [354, 403, 404]








Hydrogen peroxide Cochlea [103]
Thyroid [34, 37]
Lung [125, 354]
GI tract [152, 403, 406]
Salivary gland [403]
None reported
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disulfide isomerase (PDI) [112], and tyrosine kinase sub-
strate with 4/5 SH3 domains (Tsks4/5) [113], which may
further regulate the activity of NOX4. In addition, recent
evidence suggests that hydrogen peroxide-inducible
clone 5 (Hic-5), a focal adhesion adaptor protein, func-
tions as a negative regulator of NOX4 by promoting the
ubiquitin-proteosomal system-mediated degradation of
NOX4 [114].
NOX5
First reported in 2001, NOX5 is genetically the most dis-
tinct of the NOX isoforms [35, 115]. As shown in
Table 1, NOX5 is highly expressed in the spleen and
testis, and to a lesser extent in other tissues of the body.
Expression of NOX5 in the brain has only been docu-
mented in brain cancer, specifically glioblastoma multi-
forme [116]. As shown in Fig. 2, NOX5 is distinct from
the other NOX isoforms in that it forms fully functional
oligomers [117]. Finally, phosphorylation of NOX5 on
Thr494 and Ser498 residue has been reported to
increase its sensitivity to calcium [118].
DUOX1/2
Dual oxidases one and two (DUOX1/2) generate hydrogen
peroxide, and are named for their gp91phox domain and
their extracellular peroxidase domain. DUOX1 and
DUOX2 have been most studied in the thyroid [34, 37],
but have also been found in other parts of the body (see
Table 1). As shown in Fig. 2, DUOX enzymes interact with
DUOX activator proteins, DUOXA1 and DUOXA2,
which are critical for targeting and function of the DUOX
enzymes [119]. DUOX2 is reported to be involved in
thyroid hormone synthesis, and missense mutation of
DUOX2 results in congenital hypothyroidism [120].
DUOX1 is also expressed in the thyroid gland, but its
function in the thyroid is unknown. Recently, investiga-
tions on the DUOX enzymes have expanded to other
body systems. DUOX1 has been reported to mediate
allergic asthma [121], prolong ROS generation after
irradiation [122], and play a role in cancer development
[123]. DUOX2 has been reported to mediate keratino-
cyte inflammation [124], cochlear injury [103], and lung
injury [125]. Furthermore, both DUOX enzymes have
been implicated to be important in ROS-dependent
immunity [126].
Evidence of a role of NADPH oxidase in brain injury and
neurodegenerative disorders
There is growing evidence of a role of NOX isoforms in
brain injury and neurodegenerative disorders, particularly
for NOX1, 2, and 4. NOX activation can be increased by a
variety of inflammatory and neurodegenerative factors,
such as amyloid precursor protein (APP), amyloid β, tumor
necrosis factor-alpha (TNF-α), matrix metalloproteinase
(MMP), interleukins, and α-synucleins, as well as neuronal
damage and cell death [75, 80, 127, 128]. Evidence sup-
porting a role of NOX activation in the pathology of
ischemic and traumatic brain injury, as well as several
major neurodegenerative disorders is discussed in detail
below. Table 2 summarizes animal studies showing
effects of genetic deletion or knockdown of NOX in the
following disease models.
Stroke
NOX activation in stroke Tissue injury in stroke is
caused paradoxically by both the depletion of oxygen
(ischemia) and the replenishment of oxygen (reperfu-
sion). Increased levels of ROS have been proposed to
have clinical significance in both stages of stroke injury
[129, 130]. Furthermore, there is considerable evidence
that NOX-mediated ROS is a major mechanism of
neuronal damage in stroke pathology [12, 131–133]. To
date, NOX2 and NOX4 are the isoforms most impli-
cated to contribute to ROS generation and pathology
following cerebral ischemia, although there is also some
evidence for NOX1 involvement as well. Both focal and
global cerebral ischemia models have been used in the
study of NOX activation. Using a transient global cere-
bral ischemia (tGCI) model, our group reported a 6–7
fold elevation of NOX2 (gp91phox) membrane complex
formation, NADPH oxidase activity, and superoxide
production in the hippocampus after tGCI [132].
Additional studies revealed that NOX2 is primarily
localized in neurons and endothelial cells at early time-
points (3–6 h) after tGCI, followed by expression in
microglial cells at later time-points (72 hr) [132, 134].
Likewise, studies in focal cerebral ischemia animal
models also found that NOX2 and NOX4 mRNA and
protein, as well as NOX activity are elevated in the
peri-infarct region of the cerebral cortex from 2–48 h
after reperfusion [135–138]. Few studies have examined
later time-points, but one study found NOX2 protein
expression was markedly elevated in the peri-infarct
region of the cortex up to 2 weeks after focal cerebral
ischemia [139]. Similar to the finding in rodent models,
there is also a report that NOX4 immunostaining is
increased in neurons and vascular endothelial cells in
the cerebral cortex of human patients after stroke, al-
though the patient sample size in the study was very
small [140]. As was the case in the tGCI model, expres-
sion of NOX2 and NOX4 was noted in multiple cell
types after focal cerebral ischemia, including neurons,
astrocytes and microglia. Interestingly, superoxide pro-
duction and NOX2 expression was also shown to be
significantly elevated in mouse cerebral arteries at 24 h
after focal cerebral ischemia, and suggested to contribute
to cerebral ischemia-induced vascular dysfunction [141].
Finally, there is a single report that NOX1 protein
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Table 2 Animal studies using genetic manipulations of NADPH oxidases on neurodegenerative disorders
Disorder Animal model Genetic manipulation Manipulation Result References
Alzheimer’s Disease Aβ1–42 injection p47
phox −/− ↑M2 microglial phenotype (Ym1)
↓Monocyte chemoattractant (CCL2)
[205]










Macrophages unable to kill
APP-expressing neuroblastoma cells
[408]
Stroke tMCAO Nox1 −/− ↑Cortical (but not total) infarct [59]
tMCAO Nox1 −/− ↓Lesion, edema & BBB disruption [409]
pMCAO Nox1 −/− No change in infarct size [409]
tMCAO Nox1 −/− No change in infarct size or outcome [140]
tMCAO Nox2 −/− No change in infarct size or outcome [140]
tMCAO Nox4 −/− ↓Infarct, edema & BBB disruption
↑Cognition/basal motor function
[140]
pMCAO Nox4 −/− ↓Infarct & functional deficits [140]
tMCAO Nox2 −/− ↓Infarct [160]
tMCAO Nox2 −/− ↓Lesion & BBB disruption [158]
Perinatal Hypoxia-
Ischemia (HI)
Nox2 −/− No change in infarct size (severe hypoxia);
↑Infarct (moderate ischemia)
[410]
tMCAO Nox2 −/− ↓Infarct & spectrin cleavage
↑Neurological outcome
[131]






No change in mortality, brain water
content, or intensity of oxidative stress
[411]
[172]
ICH Nox2 −/− ↓Hematoma, edema, deficits, mortality [171]
Traumatic
Brain Injury
CCI Nox2 −/− ↓Lesion, apoptosis & ROS [185]
SBI Nox2 −/− ↑Neurological outcome [412]
Parkinson’s Disease 6-OHDA Nox2 −/− ↑Neurological outcome & resistance
to neurotoxicity
[227]
MPTP Nox2 −/− Neuroprotective [218]
MPP+ Nox2 −/− neuron-glia culture ↓Dopaminergic neurodegeneration [221]
6-OHDA Nox2 −/− ↓Rotational behavior [217]
Paraquat NOX1 −/− differentiated
human dopaminergic cells
↓α-synuclein expression & aggregation [226]
Paraquat Nox1 shRNA ↓α-synuclein expression & aggregation,




SOD1G93A Nox2 −/− ↓ROS, protein carbonylation, neurodegeneration
↑Longevity
[262]
SOD1G93A Nox1 −/− Delayed disease progression
↑Survival
[276]




SOD1G93A Nox1 +/− or Nox2 +/− ↑Survival [276]
Huntington’s Disease HD140Q/140Q Nox2 −/− ↑Neuronal viability
↓ROS
[246]
Multiple Sclerosis MOG induced EAE p47phox −/−
BV-2-myelin culture
↓ROS, neuroinflammation [308]
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expression is significantly increased in the peri-infarct
region of the cortex at 1d, 1 week, and 2 weeks after
focal cerebral ischemia, although this remains to be
confirmed [139].
An increase in NOX activation has also been reported
in studies utilizing hemorrhagic models. Enhanced
immunoreactivity to gp91phox associated with neuronal
injury and increased gp91phox mRNA expression was
reported in the rat cortex at 24 h after subarachnoid
hemorrhage (SAH) [142, 143]. Another study reported
an elevation of superoxide beginning as early as 12 h
after SAH [144]. Elevated NOX activity and superoxide
production were associated with increased membrane
translocation of the p47phox subunit [145] and increased
membrane translocation of a NOX activator Rac [144] at
24 h after SAH. The activation of NOX in SAH appears to
be short lived as one study found NOX activity return to
baseline by 48 h after SAH, with no changes in expression
of gp91phox or p22phox throughout the experiment
[145]. A similar acute NOX activation pattern was seen in
hemorrhagic stroke where NOX2 protein levels were
shown to be increased in the striatum at 12 h, and peaking
at 24 h after intracerebral hemorrhage (ICH) [146].
Gp91phox was primarily expressed in activated microglia
and colocalized with peroxynitrite at 24 h after ICH in the
injured hemisphere [147]. Human data for NOX activa-
tion in hemorrhagic stroke models are scarce, but a study
of the Chinese Han population resulted in the identifica-
tion of a p22phox polymorphism associated with
increased NOX activation and susceptibility to ICH [148].
While clearly more studies using different injury models
are needed to solidify the evidence for NOX involvement
in the pathogenesis of hemorrhagic stroke, the current
findings suggests that NOX activation is involved in the
acute phase of hemorrhagic stroke, as opposed to a more
prolonged involvement in ischemic stroke.
Neuroprotective effect of NOX inhibition in stroke
In agreement with the induction of NOX isoforms and
elevated NADPH oxidase activity after cerebral ischemia,
NOX inhibitor and knockout studies support a critical
role for NADPH oxidase in ROS generation, oxidative
stress damage, inflammation, and functional outcome
following cerebral ischemia (Table 2). For instance, a
NOX2 selective inhibitor, gp91ds-tat, but not a scrambled
control peptide, was shown to significantly attenuate the
increase in NADPH oxidase activity and superoxide level
in the hippocampal CA1 region after tGCI, and was
strongly neuroprotective when administered 30 mins
before induction of GCI [132]. Further work showed that
gp91ds-tat reduced acetylation and activation of p53 and
reduced expression of the apoptotic factor, puma in the
rat hippocampus after tGCI [149]. Many cerebral ischemia
studies have used apocynin, a non-isoform-specific NOX
inhibitor. It should be noted that apocynin has also been
reported to have direct anti-ROS scavenging ability
[150]. Nevertheless, apocynin has been shown to reduce
superoxide elevation, oxidative stress, post-ischemic
inflammation, and infarct volume, and improve neuro-
logical function in focal cerebral ischemia animal models
[131, 151–156]. These studies used a dose range from
2.5-50 mg/kg and either an intravenous or intraperitoneal
administration route in mice and rats. Apocynin treat-
ment was initiated at various times ranging from −60 min
to +120 min relative to the initiation of stroke. This indi-
cates that apocynin can be protective at least out to 2 h
after the onset of stroke, although it should be pointed out
that some dissenting studies failed to find post-stroke
protection with apocynin [140, 151], possibly due to
missing a time window of therapeutic apocynin applica-
tion or the narrow therapeutic dose range of apocynin
[155]. Interestingly, the ability of apocynin to reduce
infarct size after focal cerebral ischemia is lost in NOX2
knockout mice, suggesting its effects require NOX2 [151].
Knockout animal studies have further implicated
NOX2 and NOX4 as the principal NOX isoforms
involved in mediating oxidative stress and brain injury
following cerebral ischemia (Table 2). For instance, a
majority of studies have reported that NOX2 knockout
animals have significantly reduced infarct size following
focal cerebral ischemia [131, 153, 157–160], although
there are a few dissenting studies [140, 161]. NOX2
knockout animals also have been demonstrated to have
reduced ROS and oxidative stress in the brain after focal
cerebral ischemia [131, 159], as well as reduced blood
brain barrier disruption [158], and significantly attenuated
post-ischemic inflammation [131, 157].
Mechanistically, studies have shown that glutamate
excitotoxicity plays an important role in brain damage
following cerebral ischemia [162–164]. Recent work sug-
gests a role for NOX2 in regulating post-stroke glutamate
excitotoxicity. For instance, NOX2 has been demonstrated
Table 2 Animal studies using genetic manipulations of NADPH oxidases on neurodegenerative disorders (Continued)




MOG induced EAE p47phox −/− ↓EAE presentation [309]
MOG induced EAE p47phox splice mutation Enhanced EAE presentation [310]
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to mediate expression of complexin II, which via SNARE
signaling induces glutamate excitotoxicity [165]. Similarly,
NOX activation appears necessary for the NMDA path of
excitotoxicity. The active transmembrane complex com-
posed of p40phox, p22phox, and gp91phox produces
superoxide extracellularly and H+ intracellularly, where a
Na+/H+ exchanger removes intracellular H+ to maintain
NOX activity. When the Na+/H+ exchanger is inhibited,
NOX activity appears to decrease as shown by decreased
superoxide production and attenuated excitotoxicity [84].
These results highlight the role of NADPH oxidase in
mediating NMDA excitotoxicity.
Furthermore, there is evidence that NADPH oxidase is
critical for the release of neurotoxic factors from acti-
vated microglia after ischemia. For instance, chemical is-
chemia has been shown to induce NOX2 elevation and
ROS generation in cultured BV2 microglia cells, and
conditioned media from the activated microglia induces
robust neuronal cell death in vitro [166]. Moreover,
NOX2 siRNA knockdown or treatment with the NOX
inhibitor, apocynin blocked the cell death-inducing effect
of the activated microglia-conditioned media [166]. An
important question is what is the contribution of NOX
activation in resident microglia in the brain versus NOX
activation in circulating immune cells. Tang et. al.
attempted to address this question by performing bone
marrow chimera studies using wild-type and NOX2-KO
mice [153]. The study revealed that wild-type mice re-
ceiving NOX2-KO bone marrow had smaller infarct
sizes and less hemorrhage than NOX2 KO mice receiv-
ing wild-type bone marrow. The authors concluded that
while NOX2 from both resident brain cells and circulat-
ing immune cells contributed to ischemic brain injury
and hemorrhage, based on the bone marrow chimera
results, NOX2 from the circulating cells might contribute
more to exacerbation of brain ischemia than brain
resident cells.
Finally, in addition to the role for NOX2 in mediating
cerebral ischemia brain damage, there is one report that
showed NOX4 knockout mice have reduced oxidative
stress and neurodegeneration following focal cerebral is-
chemia [140]. Likewise, administration of the NOX in-
hibitor VAS2870 at 2 and 12 h after tMCAO also
reduces ischemic brain injury after focal cerebral ische-
mia, an effect possibly due to inhibition of NOX4 [140].
Moreover, mice engineered to overexpress NOX4 in
brain pericytes had significantly greater infarct volume
after focal cerebral ischemia, along with enhanced react-
ive oxygen species production and blood–brain barrier
breakdown in the peri-infarct region [167]. VAS2870 IV
treatment in a tMCAO model showed increased expres-
sion of microRNAs targeting NOX2 and NOX4, suggest-
ing that the neuroprotective effects of VAS2870 may
also be mediated through regulation of microRNAs
[168]. Taken together, the above studies indicate that
NOX2 and NOX4 play an important role in infarct dam-
age, inflammation and neurological deficits that occur
following cerebral ischemia.
The evidence of NOX inhibition in hemorrhagic stroke
is more limited. A study of SAH using diphenyleneiodo-
nium chloride (DPI) to inhibit NOX ameliorated the de-
creased MCA luminal diameter seen after SAH [145],
indicating a potential for NOX inhibition to reduce cere-
bral vasospasms that may complicate SAH. In studies in-
vestigating hemorrhagic transformation after ischemic
stroke, NOX inhibition via VAS2870 was able to reduce
infarct volume and attenuate NOX2 and NOX4 expres-
sion in rats, which correlated with better outcome and
reduced hemorrhagic transformation after reperfusion in
acute ischemic stroke [169]. Another study found that
apocynin treatment at high doses did not improve out-
come in a collagenase model of rat ICH [170], although
the narrow neuroprotective dose range of apocynin may
account for the lack of neuroprotection seen at high
doses [155]. Modulation of NOX expression or activity
has also been implicated in the protective effects of
hyperbaric oxygen in SAH [142, 143], Rac inhibition in
SAH [144], adiponectin paralog in ICH [146], and Bril-
liant Blue G in ICH [147]. As these treatments are not
specific in targeting NOX, the value of NOX as a thera-
peutic target in hemorrhagic stroke remains to be vali-
dated with more studies utilizing NOX-specific
inhibitors. A few knockout studies have been done in in-
vestigating the role of NOX enzymes in hemorrhagic
stroke. Gp91phox KO mice show decreased oxidative
products, reduced brain edema, smaller hematoma size,
decreased neurological deficits, and decreased mortality
as opposed to wild type mice after collagenase induced
ICH [171]. However, an endovascular perforation model
of SAH with gp91phox KO mice showed no difference
in the cerebral blood flow, brain edema, intensity of oxi-
dative stress, or mortality between WT and KO mice
[172]. It is uncertain whether different disease models or
the acute window of NOX activation in hemorrhagic
stoke may account for the variability in reported data.
These preliminary studies with NOX KO mice in
hemorrhagic stroke require further validation.
Traumatic brain injury
NOX activation in traumatic train injury In addition
to a role in stroke, there is growing evidence that NOX
activation contributes significantly to the neuropathol-
ogy of traumatic brain injury (TBI). TBI has a nearly
40% mortality rate [173] and is the leading cause of
death in young people, especially with increasing rates of
motor vehicle accidents [174]. In recent years, TBI has
gained recognition as a chronic and progressive disorder
resulting from an acute trauma [175]. The primary
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mechanical injury over time leads to development of
the secondary injury such as edema, ischemia, hypoxia,
neuroinflammation, and neurodegeneration of the cortex
and underlying hippocampus [176–178]. Oxidative stress
is thought to play a key role in the development of cere-
bral edema, breakdown of the blood brain barrier (BBB),
and the secondary neuronal damage found post-TBI. The
initial focal injury spreads via inflammatory signals to
previously healthy regions nearby and amplifies the original
tissue injury [179, 180]. BBB disruptions allow increased
permeability that contribute to the cerebral edema
following TBI [181–183].
Since oxidative stress plays a key role in TBI, several
groups have examined the role of NOX isoforms, par-
ticularly NOX2 activation in TBI pathology. Studies
from our group and others showed that NOX2 expres-
sion and NADPH oxidase activity increases rapidly in
the mouse cerebral cortex and hippocampal CA1 region
in an animal model of TBI (controlled cortical impact),
with an early peak at 1 h, followed by a secondary
peak from 24–96 h after TBI [133, 184]. The first early
peak of NADPH oxidase activity was in neurons, while
the later second peak primarily occurred in microglia
[133, 184, 185]. Further work showed that NOX2
expression remained elevated above sham controls at
7 days and 28 days post-TBI in rats [71]. At these later
stages, pro-inflammatory M1 microglia were reported
to have high NOX2 expression after TBI in a controlled
cortical impact model in mice [186]. In fact, NOX2 may
contribute to persistent microglia activation that has been
observed in the cortex chronically after TBI, as NOX2 was
found to be expressed in highly activated microglia at the
margins of the expanding lesion at 1-year after the TBI
[175]. NOX4 has also been reported to be elevated in the
cortex after controlled cortical impact or repeated
blast injury in rats [71, 187]. NOX3 was shown to be
present in neurons constitutively in both injured and
uninjured animals, and its role in TBI remains unclear
[71]. Other NOX isoforms have not been investigated
in the context of TBI.
Similar to the results obtained in animal studies
described above, immunofluorescent staining of human
post-mortem TBI brain samples showed that NOX2 and
NOX4 expression was increased in the cortex at 6–24 and
24–48 h after TBI, respectively, and abnormal NOX2 and
NOX4 expression showed correlation to patient prognosis
[188]. NOX4 expression has also been reported to be
increased in postmortem brain samples from athletes
diagnosed with chronic traumatic encephalopathy, and
the increase in NOX4 activity correlated with increased
superoxide formation [187]. Increased ROS production
and elevated expression of NOX2 has also been reported
in circulating neutrophils after TBI in humans, which
paralleled a significant increase in plasma levels of
inflammatory cytokines [189]. These findings suggest an
increased systemic inflammatory response occurs after
TBI, which may involve facilitation by NOX2. The sys-
temic inflammatory response after TBI could cause
increased local secondary damage in the brain, as well as
systemic damage to bystander peripheral tissues. Targeting
NOX inhibition in these systemic neutrophils could
potentially protect uninjured organs from secondary
damage following TBI.
Neuroprotective effect of NOX inhibition in trau-
matic brain injury To examine a potential causative
role of NADPH oxidase in TBI pathology and outcome,
investigators have used NADPH oxidase inhibitors and
NOX2 knockout animals. Administration of the NADPH
oxidase inhibitor, apocynin markedly inhibited pro-
inflammatory microglial activation and oxidative stress
damage to neurons [71, 133, 184, 190], as well as atten-
uated TBI-induction of AD-related proteins and axonal
damage markers, such as β-amyloid and amyloid pre-
cursor protein [133]. Furthermore administration of
apocynin or the more specific NOX2 inhibitor, gp91ds-tat,
induced significant neuroprotection against TBI and
reduced neurological deficits [133, 184, 191]. Administra-
tion of gp91ds-tat also altered microglia polarization after
TBI to favor the M2-like anti-inflammatory phenotype
[186], suggesting an important role of NADPH oxidase in
promoting the “pro-inflammatory” M1-like microglia
phenotype after TBI. Similarly, NOX2 knockout mice have
decreased contusion size, as well as decreased superoxide
and peroxynitrite metabolism, and a decreased number of
apoptotic cells in the cortex after TBI, confirming a pos-
sible role for NOX2 in TBI pathology [185] (Table 2).
While NOX4 has been reported to be elevated after TBI
(like NOX2) [71, 187, 188], there have been as yet no
comparable studies examining TBI pathology or outcome
in NOX4 knockout mice. Thus, studies to address this
deficit are needed.
Alzheimer’s disease
NOX activation in Alzheimer’s disease Alzheimer’s
disease (AD) is characterized by progressive memory
loss, cognitive and executive impairment, with varying
degrees of aphasia, apraxia, and agnosia [98, 192]. Early
in AD progression, cognitive symptoms are caused by
damage to the hippocampus [193, 194]. Oxidative stress,
particularly that created by NOX2 induction, has been
implicated to have a significant role in the development
of AD [24, 195, 196]. Postmortem analyses of cerebral
cortices of human AD patients showed increased
p47phox and p67phox expression and translocation to
the membrane in AD brains [196], suggesting that NOX
is activated in AD. Antemortem behavioral testing and
postmortem histopathological assessment (of frontal and
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temporal cortex) in patients with either no cognitive
impairment, preclinical AD, mild cognitive impairment,
early AD, or mild-to-moderate AD, confirmed elevation
of p47phox, p67phox, p40phox and p22phox, as well as
elevation of NOX activity in mild cognitive impairment
and AD patients [197]. There was also a robust correlation
between NOX activity and an individual's cognitive status
(e.g. as NOX enzyme activity increased, cognitive per-
formance decreased). The enhanced induction of NOX
isoforms and activity in AD, may be due, in part, to ele-
vated β-amyloid (Aβ) levels, as treatment of microglia with
Aβ has been shown to induce p47phox and p67phox sub-
unit translocation to the cell membrane, indicating an
activation of microglial NOX and ROS generation [196].
Furthermore, increased expression of NOX2 and oxidative
stress has been reported in activated microglia sur-
rounding Aβ-laden capillaries from patients with cerebral
amyloid angiopathy [198, 199].
In addition to elevation of NOX2, there is evidence
that NOX4 expression is significantly increased in the
brain of aged humanized APPxPS1 knock-in mice, and
that there is a significant linear correlation between
NOX activity and age-dependent increases of Aβ (1–42)
and cognitive dysfunction [200]. Another study showed
that NOX1 and NOX3 mRNA levels are increased in the
brain during early stages of AD [201]. Interestingly,
NOX1 mRNA levels were also reported to be signifi-
cantly elevated in the hippocampal CA1 region in a bi-
lateral cerebral artery occlusion (BCCAO) rodent model
of vascular dementia, and the effect correlated with
increased superoxide and ROS levels [202]. As a whole,
these studies provide correlational evidence of increased
NADPH oxidase subunit expression and NADPH oxidase
activity in the brain in AD, which could contribute to AD
pathology. Below we discuss evidence from inhibitor and
knockout/knockdown studies that support a role for
NADPH oxidase in AD pathology and progression.
Neuroprotective effect of NOX inhibition in Alzhei-
mer’s disease In support of NOX2 elevation having an
important pathological role in AD, treatment with the
NADPH oxidase inhibitor, apocynin markedly reduced
oxidative stress, cerebral amyloid angiopathy, and cere-
bral amyloid angiopathy-induced vasomotor impairment
in an animal model of AD (aged APP-overexpressing
Tg2576 mice) [203]. As shown in Table 2, other studies
showed that NOX2 inactivation by use of NOX2 knock-
out mice crossed with Tg2576 mice or use of the specific
NOX2 inhibitor, gp91ds-tat also significantly reduced
oxidative stress, improved the neurovascular dysfunc-
tion, and ameliorated behavioral deficits in aged Tg2576
mice [204]. Surprisingly, the beneficial effect of NOX2
inactivation in aged TG2576 mice occurred without re-
ductions in brain amyloid-beta peptide levels or amyloid
plaques. However, treatment with the NOX2 inhibitor,
gp91ds-tat or knockout of NOX2 has been shown to sig-
nificantly attenuate the ability of Aβ to induce ROS in
the brain [204], suggesting that NOX2 is a major source
of ROS induced by Aβ. Furthermore, examination of
human AD postmortem brain samples found that micro-
glia “proinflammatory” (M1) marker gene expression is
increased, while expression of the anti-inflammatory
(M2) marker genes were decreased, as compared to age-
matched controls [205]. This effect was correlated with
an increase of the NOX2 p47phox subunit in the AD
brain, and further studies revealed that p47phox KO
mice and apocynin-treated mice showed a switch from
“proinflammatory” M1 to the “anti-inflammatory” M2
microglia phenotype following induction of neuroinflam-
mation [205]. These results suggest that NADPH oxi-
dase may facilitate induction of the proinflammatory M1
microglia phenotype during neuroinflammation and AD.
Finally, while NOX1, NOX3 and NOX4 have been
reported to be elevated in AD, their precise role and
contribution to AD is currently unclear. Therefore, more
studies are needed to assess the potential role of these
NOX isoforms in AD.
Parkinson’s disease
NOX activation in Parkinson’s disease Parkinson’s dis-
ease (PD) is the second most common neurodegenerative
disorder following AD, with progressive symptoms such
as resting tremor, rigidity, akinesia, and stooped posture
caused by a characteristic loss of dopaminergic neurons in
the substantia nigra pars compacta [206–208]. Models
of PD often use the neurotoxins, 6-hydroxydopamine
(6-OHDA), paraquat, 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP) and rotenone, all of which kill
dopaminergic neurons via mechanisms that seem to
converge on oxidative stress [209]. Human PD brains
have shown evidence of oxidative damage in degenerating
areas such as the substantia nigra [210]. Post-mortem
analysis and animal studies suggest a role of inflammation
in PD pathology [211, 212], as evidenced by increased glial
activation [213], which appears to be a persistent chronic
activation [214]. Microglia have been suggested to con-
tribute to the damage of dopaminergic neurons in PD
via NOX-derived ROS [215]. In support of this conten-
tion, NOX1 expression has been reported to increase
after striatal injection of 6-OHDA and is associated
with a simultaneous increase in DNA oxidative stress
[216]. Additionally, following 6-OHDA induction, there
is an increase in NOX1 and NOX2 gene expression in
the mouse striatum, and NOX2 expression in the sub-
stantia nigra [217]. In vivo and in vitro studies of PD
induced by paraquat have shown increased expression
of NOX1 and synucleins [217]. NOX2 expression has
also been shown to increase in mouse brains after
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administration of MPTP [218] and to be elevated in PD
human brains [218]. Likewise, NOX2 and NADPH oxi-
dase activity have been reported to be increased in the
substantia nigra in an LPS-induced animal model of PD
[219]. These findings demonstrate an elevation of NOX1
and NOX2 may contribute to the dopaminergic neuronal
loss that occurs in PD. The mechanisms that lead to NOX
induction in PD are unclear; however, α-synuclein, a key
protein implicated in PD pathology, has been shown to
activate NOX2 in microglia via a process that is mediated
by the purinergic P2X7 receptor [220]. Likewise, sub-
stance P, which is dysregulated and suggested to con-
tribute to PD pathogenesis, has also been shown to
activate NOX2 in microglia, an effect critical for substance
P-induced dopaminergic neurotoxicity [221]. Other
PD-related genes have been reported to affect NOX ac-
tivation. DJ-1/Park7 can bind to p47phox to alter NOX
activation [222, 223], and silencing of DJ-1 has been
shown to increase NOX4 expression and ROS produc-
tion [224]. In addition, NOX has been implicated as a
potential mechanism underlying neuronal vulnerability as-
sociated with PINK1 dysfunction [225]. While interesting,
further studies are needed using PD models in order to
elicit whether these PD-related genes have a functional
role in mediating downstream NOX activation.
Neuroprotective effect of NOX inhibition in Parkin-
son’s disease In support of a role of NOX1 in the
pathology of Parkinson’s disease, NOX1 KO mice have
a significant attenuation of DNA oxidative stress in a
6-OHDA striatal injection PD model (Table 2) [216].
Furthermore, in both in vitro and in vivo paraquat–in-
duced PD models, NOX1 knockdown significantly
reduced α-synuclein expression and aggregation, as
well as oxidative stress and dopaminergic neuronal cell
loss [226]. With respect to NOX2, NOX2 KO mice
exhibited less dopaminergic neuronal degeneration than
their controls when lesioned by 6-OHDA [227]. Like-
wise, dopaminergic neurons from NOX2 KO mice were
significantly more resistant to rotenone neurotoxicity
(an environmental toxin linked to PD) than those from
wild-type mice [228]. The enhanced neurotoxicity of
rotenone was suggested to be due to release of NOX2-
derived superoxide from activated microglia. This sugges-
tion was supported by the fact that addition of microglia
prepared from wild-type mice, but not from NOX2 KO
mice, to neuron-enriched cultures markedly increased
rotenone-induced degeneration of dopaminergic neurons
[228]. Further evidence of a role of NOX2 in PD patho-
genesis has come from NOX inhibitor studies. For
instance, in a leucine-rich repeat kinase 2 transgenic
PD mouse model, treatment with diapocynin, an orally
active apocynin derivative, relieved early PD symptoms
regarding coordination and balance [229]. Oral
diapocynin treatment also exerted anti-inflammatory
and neuroprotective effects in a MPTP mouse model of
PD, where it preserved locomotor function and halted dis-
ease progression in a chronic mouse model of PD [230].
Furthermore, oral apocynin administration in a MPPT
monkey model of PD increased the number of surviving
dopaminergic neurons and relieved PD symptoms and
motor function deterioration [231]. Taken together, these
studies implicate a role for NOX1 and NOX2 in PD
pathogenesis and targeting them may have therapeutic
efficacy and should be explored further.
Huntington’s disease
NOX activation in Huntington’s disease Huntington’s
disease (HD) is a relentlessly progressive and fatal neuro-
degenerative disorder involving an autosomal-dominant
inheritance of trinucleotide (CAG) repeat expansion in
the huntingtin gene, which clinically manifests in chorei-
form movements, psychiatric disturbances, and cognitive
impairments [232–236]. HD shows selectivity for atrophy
and loss of medium spiny neurons in the striatum, but
eventually can lead to atrophy of the cerebral cortex at
later stages of the disease [233, 235]. Though not neces-
sarily a direct effect of the mutant huntingtin, oxidative
stress has been implicated as an important mechanism of
HD pathology as susceptible neurons may have impaired
tolerance of ROS [234, 237, 238]. Studies of human HD
brain and tissue samples found increased oxidative
damage in the caudate [239], parietal cortex [240], and
peripheral blood [241, 242] (as measured by 8-hydroxy-
2’-deoxyguanosine), in CSF (as measured by isopros-
tanes) [243], and in serum (as measured by malondialde-
hyde and 4-hydroxynonenal) [71] indicating a role of
oxidative stress in HD pathology. Furthermore, reduced
SOD antioxidant activity in the cortex and cerebellum
[239] and in erythrocytes [241] also support an impaired
antioxidant capacity in HD patients. However, the evi-
dence surrounding the presence of oxidative damage
markers in post-mortem brain tissue is not uniform
since a report exists showing unaltered levels of oxidative
DNA damage, protein carbonylation, and lipid peroxida-
tion in HD brain samples when compared to controls
[138]. Nonetheless, animal studies using transgenic
models of HD have provided a stronger consensus in the
role of ROS in HD pathology. In HD transgenic R6/2 mice
that develop a movement disorder similar to HD presenta-
tion at 14–16 weeks, the forebrain showed increased signs
of DNA oxidation at 12–14 weeks of age [244]. Despite
initial increases in SOD function after disease onset, older
mice (35 weeks) show diminished protection by SOD
[245]. Regarding potential NOX involvement in HD,
human HD patient brain lysates showed increased NOX
activity in the cortex and striatum [246]. Furthermore,
studies using a rat model of intrastriatal quinolinic acid
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injection for HD showed increased NOX-linked striatal
superoxide production that increased with the addition of
NOX substrate, NADH [247]. A model utilizing 3-
nitroproprionic acid-induced striatal lesions, which
mimics many characteristics of HD [3], likewise found
increased hydroxyl free radicals in the lesioned striatum
[248]. Furthermore, studies using a mouse model of
HD found that NOX activity was significantly elevated
in cortical and striatal synaptosomes in HD140Q/140Q mice
[246], and in primary neurons derived from HD140Q/140Q
mice [246]. A PC12 cell line in vitro study of CAG repeat-
expanded proteins also showed increased oxidative
damage attributable to NOX [14]. The emerging evi-
dence suggests a role for NOX2 in generating oxidative
stress in HD pathology; however, cell type- and isoform-
specific effects remains unexplored, and thus additional
studies are needed to address this issue.
Neuroprotective effect of NOX inhibition in Hun-
tington’s disease Despite the recent exploration of the
role of NOX enzymes in the pathogenesis of HD, there
is evidence supporting that inhibition of NOX may be
beneficial. In a rat intrastriatal quinolinic acid injection
model of HD, both pre- and post-lesion apocynin treat-
ment decreased superoxide levels and attenuated be-
havioral alterations seen in untreated, lesioned animals
[247]. Furthermore, both apocynin and DPI were able
to suppress superoxide generation after striatal lesion
in the presence of NOX substrate, NADH [247]. This
supports that NOX is actively participating in the path-
ology of this model of HD. Apocynin and DPI treat-
ment of primary cortical and striatal neurons derived
from HD140Q/140Q transgenic mice reduced NOX
enzyme activity to the levels of WT neurons [246], as
well as reduced ROS generation, increased viability, and
improved morphology of the neurons [246]. These
HD140Q/140Q derived neurons also showed increased
neuronal viability when treated either with a superoxide
quencher, EUK189, or a more selective NOX inhibitor,
VAS2870 [246]. Though VAS2870 has been reported as
a selective NOX2 inhibitor, other studies have revealed
its effect on other NOX isoforms and cannot be used to
implicate NOX2 as the key NOX isoform in HD pathology.
However, NOX2 involvement can be studied using
gp91ds-tat, a more selective inhibitor of NOX2 [249]. In
the PC12 cell line, treatment with gp91ds-tat reduced ROS
levels, dissolved nuclear aggregates induced by expanded
polyglutamine peptides, and prevented the formation of
new aggregates [14], suggesting that NOX inhibition
may be beneficial. Though investigations on the role of
NOX2 in HD is a recent endeavor, results so far seem to
suggest a key role of NOX2 involvement in HD pathology.
In support of this possibility, cortical neurons derived
from NOX2-deleted HD140Q/140Q mice showed reduced
NOX activity and increased cell survival as compared to
NOX2-WT HD140Q/140Q mice [246]. These results suggest
that NOX2 inhibition can be neuroprotective, and that
further studies utilizing NOX2 KO mice in HD models
are needed to further confirm the role of NOX2, as well
as the potential benefits of NOX inhibition on behavioral
parameters, cognitive health, and disease outcome. In
addition, additional studies testing the role of other NOX
isoforms in HD pathology are also needed.
Amyotrophic lateral sclerosis
NOX activation in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is characterized by
progressive motor neuron degeneration and subsequent
gliosis that burdens patients with muscle weakness and
disability, eventually leading to fatal respiratory and car-
diac deficits within 3–5 years of diagnosis [250, 251].
Despite over 30 years of research using animal models,
only a single drug has been approved for the treatment
of ALS (riluzole), and its effect on survival is modest
[252]. Although the exact mechanism of motor neuron
death in ALS is still under investigation, oxidative stress
has been implicated in the disease progression [253, 254].
Patients suffering from either sporadic or familial ALS
showed increased oxidative stress markers such as protein
carbonylation [255], nitration of protein-tyrosine residues
[256], lipid peroxidation [257], protein glycoxidation
[257], and mRNA oxidation [258] in their spinal cords.
Furthermore, similar increases in oxidative stress markers
have also been detected in the brain [259] and CSF [260]
of ALS patients. Despite an account where nitrotyrosine
was not found to be significantly elevated in the CSF of
ALS patients [261], there appears to be a consensus that
oxidative stress plays a role in ALS pathology. In par-
ticular, post-mortem spinal cord samples from patients
with sporadic ALS showed a 3-fold increase in NOX2
expression and increased protein carbonyl adducts than
in control post-mortem samples [262]. An animal
model commonly used to study ALS is the overexpression
of mutant superoxide dismutase one (SOD1), since
dominant mutations in SOD1 lead to familial ALS in
humans [263]. SOD1 overexpression likely leads to motor
neuron damage due to the increase in oxidative stress, in
part due to NOX activation. In the most widely used
mouse model of ALS (SOD1G93A), NOX2 is upregulated
in the ALS mice [262]. Furthermore, ALS mice overex-
pressing SOD1 had enhanced NOX-dependent superoxide
production in the brain and spinal cord [264]. Rac1, an
important regulator of NOX, was reported to directly
interact with SOD1 [264]. Altered Rac1 modulation by
mutant SOD1 (SOD1L8Q) has been implicated in the per-
sistence of NOX dependent superoxide production [264],
and binding of mutant SOD1 to Rac1 has been suggested
to amplify microglial NOX2 production of ROS [265].
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Likewise, human astrocytes that overexpress mutated
SOD1 (SOD1G37R) up-regulate NOX2 [266]. In addition
to evidence of NOX2 elevation in ALS, human whole
genome analysis of sporadic ALS patients linked NOX4 to
have a possible role in ALS disease progression [267].
Neuroprotective effect of NOX inhibition in amyo-
trophic lateral sclerosis Since oxidative stress is impli-
cated in the pathogenesis of ALS, antioxidants have
been evaluated for their efficacy to limit disease progres-
sion. However, clinical trials based on antioxidants in
ALS have been unsuccessful. For instance, Vitamin E
[268–270], coenzyme Q10 [271, 272], and edaravone
[273], despite slowing motor neuron degeneration in
mice SOD1G93A model [274], are a few tested antioxi-
dants and free radical scavengers that have shown no
major improvements or limited improvement in quality
of life in ALS clinical trials. The lack of translational effi-
cacy may be partially due to pharmacological inability to
cross the BBB, variability in experimental conditions, or
generalized drug mechanisms that overlook the value of
targeting a specific oxidative pathway. Based on the
potential role of NOX enzymes in ALS pathology, it is
reasonable to investigate whether targeting of NOX can
be therapeutic. Studies investigating NOX’s role in
human ALS patients found that patients that had lower
NOX2 activity in their peripheral blood cells showed sig-
nificant increases in survival [275]. Additionally, ALS
mice deficient in NOX2 showed decreased oxidative
stress in spinal cords and a modest increase in lifespan
(Table 2) [262]. Likewise, ALS mice having either dele-
tion of NOX1 or NOX2 showed increased survival and
delayed disease onset, and these effects are greater in the
NOX2 deleted ALS mice [276]. Interestingly, female
ALS mice heterozygous for either NOX1 or NOX2 also
showed significantly increased survival [276]. Apocynin
treatment was also shown to improve motor neuron
survival when co-cultured with astrocytes carrying a
mutant SOD1 (G37R) [266], further supporting that
NOX inhibition can have a neuroprotective role in
ALS. Pharmacological inhibition of NOX has also shown
benefits in animal models of ALS. For example, long-term
treatment with apocynin beginning at an early age
(2 weeks) prolonged survival by nearly 50% and increased
the number of motor neurons in the spinal cord in
hemizygous SOD1G93A mice [264], showing that NOX
inhibition can delay ALS progression. Apocynin treat-
ment initiated at a later age (80 days) also showed
decreased disease progression, although the effect was
minor [264]. In contrast to the above study, another
study reported little beneficial effect of apocynin or diapo-
cynin on extending the lifespan in the SOD1G93A model
[277]. Clearly, further studies are needed to clarify the role
of NOX isoforms in ALS. Use of inducible and cell-
specific NOX subunit KO models may also add further
clarification and avoid confounds of global KO models.
Multiple sclerosis
NOX activation in multiple sclerosis Multiple Sclerosis
(MS) is a chronic CNS disease of autoimmune origin that
leads to demyelination, impaired motor function, and
neurodegeneration [7, 278–282]. Inflammation and
neurodegeneration are some of the key characteristics
of MS [7, 282, 283]. Accumulating evidence suggests
that oxidative stress plays a key role in MS pathology
[281, 284–287]. Brain samples from human patients
affected with MS show increased signs of oxidative
damage to DNA, proteins, and lipids within and outside
of MS plaques in the brain [288–294]. It has been sug-
gested that NOX in activated microglia contributes to
the production detrimental ROS and plays an important
role in MS pathogenesis [295]. NOX2, NOX1, and
NOXO1 were shown to be upregulated in activated
microglia found in active demyelinating and chronic MS
lesions sampled from human MS patient brain tissue
[296]. Furthermore, NOX2 was also upregulated in acti-
vated microglia in pre-active MS lesions found throughout
normal appearing white matter of MS patients [297], sug-
gesting a role of activated microglia in the production of
ROS in MS. However, a protective role of ROS has been
suggested as decreased ROS production by isolated per-
ipheral blood leukocytes from MS patients were associated
with a more severe MS presentation [298]. This suggests
that the role of microglia and NOX-mediated ROS pro-
duction may be more complicated and would need further
animal model studies to elucidate the role of NOX in MS
pathology. In animal studies, experimental autoimmune
encephalomyelitis (EAE) is the most commonly used
model to simulate pathological and clinical findings of MS
[299]. However, it has been reported that notable differ-
ences in observed tissue injury and oxidative stress exist
between human MS and animal EAE models where EAE
models potentially underrepresent the extent of injury
found in human MS studies [300]. Thus, the NOX activa-
tion seen in the EAE studies may actually be greater in the
human MS model. In vitro, NOX has been shown to
increase BBB permeability of brain endothelial cells in
EAE [301]. In EAE induced mice, the brain and spinal
cord exhibit increased NOX enzyme activity and NOX
expression as compared to that of control mice [302, 303],
suggesting that NOX activity may contribute to tissue
damage in the course of EAE. In particular, NOX2 and
the subunits p67, p47, p40, and p22phox mRNA showed
increase in both relapsing-remitting and chronic models
of EAE [304], indicating a probably increase in oxidative
stress during the peak stages of EAE and in the later pro-
gressive stage of EAE. In a different study, NOX2 expres-
sion was also seen to be elevated in microglia during
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remission phases of relapsing-remitting EAE [305], which
coincided with observed impairments in hippocampal
CA1 synaptic plasticity [305]. Despite possible differences
between EAE and MS, animal models of EAE have fur-
thered our knowledge on the role of NOX in disease
progression.
Neuroprotective effect of NOX inhibition in multiple
sclerosis The use of EAE animal models in conjunction
with NOX inhibition techniques show a more causative
role of NOX that may be contributing to MS pathology.
In EAE in vitro studies, NOX inhibition with apocynin was
able to reduce BBB permeability seen in EAE [301, 306].
Early studies have shown that blocking NOX via apocynin
or DPI reduces ROS formation and prevents phagocytosis
of myelin [307]. Similar results were obtained by either
blocking NOX assembly or by deletion of p47phox, where
ROS production and neuroinflammation were both
attenuated in a model of isolated myelin and primary
microglial culture [308]. Studies of the p47phox subunit
report a complex function. Mice with p47phox deletion
develop decreased EAE, showing no obvious signs of
EAE as compared to WT mice who developed modest
of severe disease after EAE induction [309]. However,
mutant mice with truncated or nonfunctional p47phox
proteins showed enhanced disease progression after
EAE induction [310], indicating that the oxidative burst
of NOX enzymes may serve a beneficial role in modu-
lating disease progression. Nonetheless, more studies
have reported benefits of NOX inhibition. Isolated
microglia from NOX2 KO mice showed reduced toxicity
to oligodendrocytes [295]. Inhibition with DPI also pre-
vented activated microglia from killing oligodendrocytes
[295]. In vivo, NOX2 deletion in mouse models of EAE
prevented the weight loss, attenuated oligodendrocyte
loss, and reduced microglia reactivity that were all
observed in WT EAE mice [311]. Deletion of NOX2 also
improved neurological outcome in EAE mice [311],
showing that these NOX2 KO mice are more resistant
to EAE. Mice treated with apocynin to inhibit NOX
also showed reduced clinical symptoms of EAE, reduced
demyelination, and reduced infiltration of immune cells
[306]. It has also been shown that apocynin can reduce
synaptic plasticity in the hippocampal CA1 region during
a remission phase of EAE [305]. The evidence based on
genetic studies of NOX deletion and inhibition demon-
strates that modulation of NOX can therapeutically inhibit
some clinical features and neuropathological changes
associated with EAE, and ultimately MS.
Translational relevance - NOX inhibitors as potential
therapeutic agents
Although there is much promise in using a NOX
inhibitor for the management of brain injury and
neurodegenerative disorders, preclinical studies have
been limited due to many factors. To date, preclinical
ROS scavenging trials lack consistency in demonstrating
their beneficial effects [312] despite showing promise in
animal studies. The lack of translational success could
possibly be due to issues with targeting within the thera-
peutic window, animal model adequacy, the sample size,
and bioavailability [313]. The evidence discussed above
supporting a role of NOX in brain injury and neuro-
degeneration has provided impetus towards examining
the therapeutic efficacy of NOX inhibitors in these
disorders [73], as this approach may offer the best
therapeutic option for treating disorders associated
with oxidative stress [314]. One challenge that NOX
inhibitors must overcome for successful translation to
the clinic is the timing of application. Most inhibition
studies referenced in the above sections have been
initiated before injury or during the acute phase of the
disease immediately following injury. Not enough studies
have been done in exploring whether delayed inhibition of
NOX at later time points following injury may offer
different therapeutic effects, especially in disease
models where NOX activation post-injury is prolonged.
Since NOX inhibition at later time points are more rele-
vant to a clinical setting, more exploration in the early ver-
sus late inhibition can increase the success of translating
NOX inhibitors to clinical models. Challenges also exist in
determining the optimal treatment window for chronic
neurodegenerative disorders that progress over many
years, where no single injury, such as in stroke or TBI, is
the root of disease. In chronic neurodegenerative diseases,
NOX inhibition may aim to primarily modulate the
chronic inflammation that exacerbates disease progress.
Future studies utilizing NOX inhibitors should pay atten-
tion to the acute or chronic nature or studied disease
models. In the sections below, we discuss the utility of
various isoform-specific and non-specific NOX inhibitors,
as well as more challenges that still need to be met for suc-
cessful translation to the clinics.
Non-specific NOX inhibitors
Apocynin Apocynin is perhaps the most studied drug of
all the available NOX inhibitors. It was isolated from the
medicinal plant Picrorhiza kurroa and inhibits NOX2
via preventing the membrane translocation of p47phox
and p67phox [315–320], without interfering with
physiological intracellular killing and defense mecha-
nisms [319]. Apocynin also reduces oxidative damage
by scavenging hydrogen peroxide and hypochlorous
acid in phagocytic cells [150, 321]. Apocynin inhibition
of NOX in neutrophils was reported to require myelo-
peroxidase [150]. Some potential advantages of apocynin
as a potential therapeutic agent in neurodegenerative dis-
orders include its reported low toxicity and ability to pass
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the BBB [203, 277, 322], and its documented ability in
Phase I clinical studies to reduce oxidative stress after
aerosol administration [317, 323]. A potential disadvan-
tage of apocynin as a therapeutic agent could be its
reported “off target” direct ROS scavenging effects. How-
ever, as mentioned previously, apocynin-induced neuro-
protection against ischemic injury has been shown to be
lost in NOX2 knockout animals [157], suggesting its neu-
roprotective effects are NOX2 dependent. In addition, as a
therapeutic agent, having other ROS inhibiting effects
such as scavenging ROS may not necessary be a negative,
as multimodal ROS inhibition could actually lead to a
greater efficacy and improved therapeutic outcome.
DPI Diphenyleneiodonium chloride (DPI) has been used
as an inhibitor of NOX in both in vivo and in vitro studies
investigating oxidative stress in neurodegenerative disor-
ders [145, 246, 247, 307]. DPI accepts an electron from
flavin, thereby preventing the generation of ROS [324].
However, this mechanism of action allows DPI to
inhibit other flavoenzymes. Thus, it is unlikely that DPI
is selective for a specific NOX isoform. In addition to
inhibiting NOX [325], DPI inhibits activities of NOS
[326], xanthine oxidase, and cyp450 enzymes [246, 324],
and blocks potassium and calcium currents [327], sug-
gesting a nonselective ion channel blocking function
that can protect neurons against glutamate excitotoxi-
city [328]. Despite its nonspecific action and high toxicity
[329], at micromolar doses, DPI has been reported to in-
hibit NOX without any off target activities [330], opening
the exploration of optimum dosage in evaluation of a
drug’s specificity for NOX. Nonetheless, development of
more targeted approaches using specific NOX inhibitors
is considered most needed by the field, so as to avoid
inhibition of all NOX isoforms, which could lead to
increased risk of negative side effects in patients.
NOX2 specific inhibitors
Gp91ds-tat Gp91ds-tat is reported to be a specific and
efficacious peptide inhibitor that binds directly to NOX2
to impair its activity [249, 331]. Introduced in 2001,
gp91ds-tat is a chimeric peptide that inhibits the asso-
ciation of p47phox with gp91phox and thus inhibits
ROS production by NOX [249]. GP91ds-tat is specific
for NOX2-containing gp91phox and not xanthine oxidase;
however due to the homologous structure between NOX1
and NOX2, gp91ds-tat may also inhibit the assembly of
NOX1 [249], as well as its activity [331]. In a cell free sys-
tem, gp91ds-tat inhibits NOX activity up to 80%, and does
not act as a scavenger of superoxide, but this inhibition is
reduced to roughly 35% in intact human neutrophils
[249], possibly due to the cell’s ability to overcome such
an inhibition. Despite efficacy in animal models,
gp91ds-tat has very limited oral bioavailability, and thus
requires intravenous administration. It is also not clear
whether it can pass the BBB.
GSK2795039 GSK2795039 is a novel, small molecule
NOX2 inhibitor that has been shown to inhibit NOX2-
dependent ROS generation. In vitro characterization
defined GSK2795039 as a reversible, direct inhibitor of
NOX2, while in vivo studies showed brain penetrance
with systemic administration [332]. This compound has
been tested in a mouse model of acute pancreatitis to
show reduced pancreatic cell necrosis [332] paralleling
results found in gp91phox knock out mice [333]. How-
ever, preclinical studies are needed to test the efficacy of
this novel small molecule NOX2 inhibitor in brain injury
and neurodegenerative disorders.
NOX selective inhibitors
VAS2870 VAS2870 is a low molecular weight NOX
inhibitor that can maintain basal ROS production in a
model of endothelial cells [334] while decreasing ROS
due to NOX. Though specific for NOX, VAS2870 does
not appear to differentiate between specific NOX
isoforms, including DUOX. Because of the variability in
subunits amongst the NOX and DUOX enzymes,
VAS2870 is thought to act on a common core flavocyto-
chrome [335], but does not appear to inhibit other clas-
ses of flavoenzymes [70]. In an ischemic stroke animal
model, administering VAS2870 intrathecally several
hours after cerebral ischemia offered the same protec-
tion as deletion of NOX4, which was implicated as the
source of ROS in this particular model [140]. However,
VAS2870 has been reported to inhibit other NOX iso-
forms as well. For instance, in a liver tumor model,
VAS2870 inhibited NOX1 [336], while it also inhibited
DUOX-induced ROS in a model of zebrafish wound
healing [337]. Additionally, there are some contradic-
tions found in the mechanism of action of VAS2870. It
has been cited to inhibit NOX2 in whole cell lysates
[338], and even as a direct NOX2 inhibitor [339]; yet,
another study suggests an inhibitory action upstream of
NOX2 because the originally proposed NOX2 inhibition
was not seen in a purified enzyme preparation [340]. A
structurally similar analogue, VAS3947 shows higher
solubility but is similarly nonspecific to the various
NOX isoforms [70]. Though VAS2870 has been validated
as an inhibitor of NOX, its lack of specificity to NOX
isoforms, low solubility, and need for intrathecal route
of administration make it unlikely to be successful for
treatment of brain injury or neurodegenerative disorders
in humans.
GKT-136901 Identified in 2010, GKT-136901 is a novel
inhibitor of NOX that has high specificity for NOX1 and
NOX4, with low affinity and partial inhibition of NOX2
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[341], and low affinity and low to no inhibition of other
ROS producing enzymes [341, 342]. This novel dual-
inhibitor has also shown ability to scavenge peroxyni-
trite, which may prove useful therapeutically [343], but
may confound studies utilizing GKT-136901 to investi-
gate specific roles of NOX isoforms in disease pathology.
GKT-136901 has high oral availability and in vivo
plasma concentrations after administration [342], but its
ability to pass the BBB is unclear. Since it is a selective
NOX inhibitor and not single isoform specific, the
potential for side effects may be increased.
GLX351322 A newly developed NOX inhibitor,
GLX351322, is proposed to have relatively higher select-
ivity to NOX4 over NOX2. In a model of type 2 dia-
betes, GLX351322 treatment prevented ROS production
and death in human islet cells [344]. Due to it only being
recently developed, studies are needed to further con-
firm the specificity of this novel inhibitor and establish
its ability to target NOX therapeutically in brain injury
and neurodegenerative disorders.
Translational challenges and emerging concepts
While we have learned much about the biology, function
and targeting of NOX subunits in the last decade, much
more needs to be known. Several major challenges
remain that must be met in order to translate basic dis-
coveries in the field to effective therapies in the clinic. In
the next section, we summarize these challenges and
some potential solutions and future directions that may
help move the field forward.
The need for inducible, cell-type and NOX isoform specific
knockout models
All of the mutant animal studies discussed in this review
used global knockout animal models. While these studies
have yielded important insights, global knockout models
are not without limitations. For instance, it is often diffi-
cult to distinguish primary versus secondary effects in
global KO models. Furthermore, the knockout is life-
long, including throughout development, which could
cause developmental confound and/or compensation
issues. Finally, in global knockout animals the NOX
gene is knocked out in multiple different cell types, and
thus one cannot easily determine the role of a particular
NOX- expressing cell type in a specific process or dis-
order. To address these limitations, the field would benefit
from development of inducible, cell-specific NOX subunit
knockout approaches in animal models of brain injury
and neurodegenerative disorders. With the recent advent
of CRISPR-Cas9 and related gene editing technologies,
knockout model generation has become more cost
effective and less time consuming, which should spur
more rapid progress toward this goal. In addition to use
of this technology in mice, it would be advantageous to
also extend the inducible, conditional NOX knockout
animal development to rats, so as to further confirm
results in a different species.
The challenge of developing specific NOX inhibitors that
lack significant side effects
An additional major challenge to the field is how to
develop NOX inhibitors that avoid “off target” and non-
specific effects, and have reduced potential for negative
side effects in patients. It has been suggested this may
be achieved through development of isoform-specific
inhibitors that target only a specific NOX isoform. In-
deed, effort has already been devoted to development of
such isoform-specific NOX inhibitors, which is expected
to continue and grow. In addition to inhibitors, another
possibility for isoform-specific NOX inhibition is siRNA
knockdown. However, delivery of siRNAs to the brain is
a challenge and requires more work and study before
this would be a viable translational approach. Alterna-
tively, a new approach that may yield effective isoform-
specific NOX inhibitors is aptamer technology [345–348].
Aptamers are single-stranded nucleic acids that bind to
their targets with high affinity and specificity and can
directly block or interfere with the functions of the target
proteins [348]. In addition, aptamers can be designed to
penetrate the blood brain barrier [347, 349], can deliver
additional therapeutic cargos (such as siRNA) to cells in a
cell-type specific manner [346, 348, 350], and can be
reversible [351]. Cell-type specific targeting could help
avoid side effects by restricting inhibition to the major
cell-type implicated in the pathology.
An additional therapeutic concern for most of the
available NOX inhibitors is that they would inhibit both
pathological and physiological NOX signaling. This is a
significant concern, as inhibition of physiological NOX
signaling could lead to significant side effects, especially
when chronic NOX inhibition is utilized (which likely
would be needed in chronic neurodegenerative disor-
ders). Therefore, consideration must be given to strategies
that would lead to interventions that would only inhibit
pathological NOX signaling. This might be achieved by
targeting critical interactions of NOX isoforms proteins
with other proteins necessary for NOX to become active
in pathological situations. Since aptamers have high
specificity and affinity, and can be chemically modified
to interfere with specific protein-protein interactions
[352], aptamers technology might be one way to explore
development of inhibitors that target only pathological
NOX signaling. Furthermore, it is known that some NOX
subunits require post-translational modification for activa-
tion [353]. Since aptamers can be designed to recognize
post-translational modified sequences [348], they
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potentially could also be useful to inhibit post-
translationally “activated” NOX subunits.
The challenge of balancing NOX activity for regenerative
medicine
While NOX activation has a role in the pathology of brain
injury and neurodegenerative disorders, it is currently
unknown whether it plays any role in regeneration of the
brain after injury. Intriguingly, it is known that there is an
increase in adult neurogenesis following various brain
insults, including stroke [232, 354], TBI [233, 234], and
even in certain stages of neurodegenerative disorders such
as AD [235, 236]. Furthermore, recent work has shown
that NOX2 is colocalized in neural stem cells in the sub-
ventricular zone, suggesting it may have a role in regula-
tion of neurogenesis [241]. In support of this possibility,
both in vivo and in vitro studies have recently shown that
ROS generation and the activation of NOX enzyme are
essential for the proliferation and self-renewal capacity of
neural stem/progenitor cells [241, 242, 244, 245]. Under
physiological conditions, it has been suggested that the
ROS generation in the stem cell “niche” is mediated by
NOX2, as (i) NOX2 expression was detected in neural
stem cells and increased when these cells were stimulated
with mitogen factors to promote proliferation [242, 245];
(ii) NOX2-deficient mice show decreased neurogenesis in
the sub-ventricular zone and the dentate gyrus, two
major regions well documented for adult neurogenesis
[242, 244]; and (iii) cultured neural stem cells obtained
from adult NOX2-deficient mice show decreased prolifera-
tion and self-renewal capacity [242, 244]. These studies
only examined basal neurogenesis in a non-injury and
non-neurodegenerative context. Given that brain injury
can markedly elevate levels of ROS and NOX activation,
additional studies are needed to examine whether
NOX2-derived oxidative stress, influences the prolifera-
tion, self-renewal capacity, and cell-fate determination
of both endogenous and exogenous neural stem cells
following brain injury and in neurodegenerative disor-
ders. Such studies could yield important new insights
on the role of NOX in repair and regeneration of the
brain, and help better inform future development strategies
for therapeutic NOX intervention in brain injury and neu-
rodegenerative disorders. Furthermore, the role of NOX in
the vasculature needs to be considered when utilizing
therapeutic NOX intervention. NOX enzymes are reported
to promote angiogenesis: (i) NOX1 inhibition in endo-
thelial cells reduce angiogenesis [355]; (ii) NOX4 is
reported to have a protective role via enhancing pro-
angiogenic signaling after hypoxia in cardiac tissue [356];
and (iii) BDNF induces NOX activation via p47phox phos-
phorylation promoted angiogenesis in vascular endothelial
cells [357]. There may also be differential regulation of
NOX isoforms in the vasculature in response to different
neurodegenerative disorders, which may lead to variability
in the potentially negative effects of utilizing non-selective
NOX inhibitors. NOX inhibition has also been reported to
affect synaptic plasticity and LTP induction [358]. Poten-
tial negative effects on the cerebrovasculature and neuro-
plasticity need to be considered when using NOX
inhibitors. Despite potential pitfall of NOX inhibitors to
alter physiological processes, it is important to note that
apocynin has been used in clinical trials with low observed
toxicity and no significant side effects [317, 323], sup-
porting the continued pursuit of NOX inhibitors as
potential therapy for neurodegenerative disorders.
Conclusions
There is significant evidence that NOX subunits and
NOX activity are elevated in various neurodegenerative
disorders, and that genetic ablation and pharmacological
inhibition studies support the possibility of targeting
NOX subunits for therapeutic benefit in neurodegenerative
disorders. However, clearly there still remain many chal-
lenges ahead for the discovery of effective and NOX-
specific targeting that would yield benefit in neurode-
generative disorders while minimizing negative side
effects and generating a healthy neuronal environment
for neurogenesis. While addressing these challenges
remains problematic, the continued advancement of
technology offers hope that realization of this goal may be
achievable in the near future.
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